carbidopa/levodopa / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 61 Diseases   24 Trials   24 Trials   800 News 


«12...234567891011121314»
  • ||||||||||  carbidopa/levodopa / Generic mfg.
    [VIRTUAL] Catatonia, Parkinsonism and Dystonia in a patient with Osmotic Demyelination Syndrome () -  Sep 20, 2020 - Abstract #MDSCongress2020MDS Congress_209;    
    Patients generally exhibit a biphasic course that initially manifests as encephalopathy or seizures, followed thereafter by neurological deterioration characterized classically by variable tetraparesis, bulbar palsy, coma or locked-in state. The varied topographical localization of lesions in extrapontine myelinolysis leads to many different clinical symptoms including altered consciousness, emotional lability, ataxia, tremor, myoclonus, akinetic mutism, catatonia, dysautonomia, quadriparesis, and later progression to dystonia, choreoathetosis or parkinsonism.
  • ||||||||||  carbidopa/levodopa / Generic mfg.
    [VIRTUAL] Early-onset peak dose Levodopa induced dyskinesia in elderly Ethiopian Parkinson’s disease patient () -  Sep 20, 2020 - Abstract #MDSCongress2020MDS Congress_147;    
    In the absence of the usual risk factor for early development of L-dopa induced dyskinesia, exposing a treatment-naive PD patient to a higher dose of dopamine is often associated with early occurrence of drug-induced (Levodopa-induced) dyskinesia. So, we recommended all treating physicians to initiate  PD patients with low dose L-dopa and titrate the dose gradualy, since resource limited countries like our didnot have the luxury to give alternative drugs.
  • ||||||||||  bupropion / Generic mfg., amantadine / Generic mfg.
    [VIRTUAL] Amantadine-induced negative myoclonus in a patient with Parkinson’s disease: A case report () -  Sep 20, 2020 - Abstract #MDSCongress2020MDS Congress_145;    
    The mechanism of amantadine-induced myoclonus is unknown but may be related to its NMDA receptor antagonistic properties. As demonstrated in this case, amantadine-induced myoclonus does not appear to be dose-related as the patient’s myoclonus did not improve after his dose of amantadine was halved. Our case was unique due to the presence of asterixis with postural tasks and standing, which has not been described previously.
  • ||||||||||  carbidopa/levodopa / Generic mfg., Duodopa (levodopa/carbidopa intraduodenal gel infusion) / AbbVie
    Clinical, Journal:  Complex dyskinesias in Parkinson patients on levodopa/carbidopa intestinal gel. (Pubmed Central) -  Sep 2, 2020   
    Atypical biphasic, biphasic-like and complex dyskinesias could hinder the course of patients treated with levodopa infusion. This study further informs the selection process of advanced therapies, particularly in dyskinetic patients.
  • ||||||||||  Trial completion, Trial completion date, Trial primary completion date:  Inflammation-related Alterations in Neurocircuitry: Reversal With Levodopa (clinicaltrials.gov) -  Aug 25, 2020   
    P4,  N=57, Completed, 
    This study further informs the selection process of advanced therapies, particularly in dyskinetic patients. Recruiting --> Completed | Trial completion date: Jun 2021 --> Aug 2020 | Trial primary completion date: Jun 2021 --> Feb 2020
  • ||||||||||  carbidopa/levodopa / Generic mfg.
    Enrollment open, Enrollment change:  L-DOPA vs. Placebo for Depression and Psychomotor Slowing in Older Adults (clinicaltrials.gov) -  Aug 8, 2020   
    P4,  N=90, Recruiting, 
    He was able to regain most of his baseline functional status with intensive rehabilitation. Suspended --> Recruiting | N=30 --> 90
  • ||||||||||  carbidopa/levodopa / Generic mfg.
    [VIRTUAL] A Review of Long Term Levodopa Use and the Development of Arrhythmias (Poster Area) -  Aug 5, 2020 - Abstract #ECNP2020ECNP_1147;    
    There was also no significant difference in the incidence or severity of ventricular arrhythmias when comparing different levodopa preparations (e.g. levodopa alone compared to carbidopa and levodopa)...In future, more research is required into this topic in order to fully elucidate the types of arrhythmias most commonly associated with levodopa use. Furthermore, studies should concentrate on the relationship between the dosage and route of levodopa use in terms of the development of arrhythmias, as this is an area which has only briefly touched upon in research.
  • ||||||||||  rivastigmine / Generic mfg., quetiapine / Generic mfg.
    [VIRTUAL] Prolonged Therapy of Dementia with Lewy Bodies with Quaternary Ammonium Anti-Muscarinic/High-Dose Cholinesterase Inhibitor (QAAM/HDCI) () -  Aug 2, 2020 - Abstract #AAIC2020AAIC_3342;    
    The results show that prolonged symptomatic, cognitive and functional improvement of dementia with Lewy Bodies is possible with the high-level inhibition of central nervous system cholinesterase achievable when rivastigmine is combined with glycopyrrolate. The discussion correlates these observations with current experimental, clinical and epidemiological evidence regarding the mechanism and treatment of this, and other, neurodegenerative diseases.
  • ||||||||||  Trial completion date, Trial primary completion date:  Neurobiological Drivers of Mobility Resilience: The Dopaminergic System (clinicaltrials.gov) -  Jul 1, 2020   
    P1/2,  N=14, Recruiting, 
    The discussion correlates these observations with current experimental, clinical and epidemiological evidence regarding the mechanism and treatment of this, and other, neurodegenerative diseases. Trial completion date: Aug 2023 --> Apr 2021 | Trial primary completion date: Aug 2023 --> Apr 2021
  • ||||||||||  carbidopa/levodopa / Generic mfg.
    Trial completion date, Trial suspension, Trial primary completion date:  Sinemet for Spasticity and Function in Amyotrophic Lateral Sclerosis and Primary Lateral Sclerosis (clinicaltrials.gov) -  Jun 11, 2020   
    P1,  N=15, Suspended, 
    N=60 --> 14 Trial completion date: May 2020 --> May 2021 | Enrolling by invitation --> Suspended | Trial primary completion date: May 2020 --> May 2021
  • ||||||||||  Trial completion date, Trial primary completion date:  Inflammation-related Alterations in Neurocircuitry: Reversal With Levodopa (clinicaltrials.gov) -  May 22, 2020   
    P4,  N=80, Recruiting, 
    Trial completion date: May 2020 --> May 2021 | Enrolling by invitation --> Suspended | Trial primary completion date: May 2020 --> May 2021 Trial completion date: Jun 2020 --> Jun 2021 | Trial primary completion date: Jun 2020 --> Jun 2021
  • ||||||||||  Enrollment closed, Trial completion date, Trial primary completion date:  Gait Analysis in Neurological Disease (clinicaltrials.gov) -  May 6, 2020   
    P=N/A,  N=120, Active, not recruiting, 
    Trial completion date: Jun 2020 --> Jun 2021 | Trial primary completion date: Jun 2020 --> Jun 2021 Recruiting --> Active, not recruiting | Trial completion date: Oct 2020 --> Jun 2021 | Trial primary completion date: Oct 2020 --> Jun 2021
  • ||||||||||  Inbrija (levodopa inhalation powder) / Acorda
    Review, Journal:  Levodopa Inhalation Powder: A Review in Parkinson's Disease. (Pubmed Central) -  Apr 23, 2020   
    Levodopa inhalation powder was generally well tolerated and did not noticeably affect pulmonary function in PD patients. Providing a nonintrusive, convenient treatment method, levodopa inhalation powder is a promising option for the intermittent treatment of OFF episodes in patients with PD treated with a LD-DCI.
  • ||||||||||  carbidopa/levodopa / Generic mfg.
    Trial suspension:  L-DOPA vs. Placebo for Depression and Psychomotor Slowing in Older Adults (clinicaltrials.gov) -  Apr 20, 2020   
    P4,  N=30, Suspended, 
    Providing a nonintrusive, convenient treatment method, levodopa inhalation powder is a promising option for the intermittent treatment of OFF episodes in patients with PD treated with a LD-DCI. Active, not recruiting --> Suspended
  • ||||||||||  carbidopa/levodopa / Generic mfg.
    Enrollment closed, Enrollment change:  L-DOPA vs. Placebo for Depression and Psychomotor Slowing in Older Adults (clinicaltrials.gov) -  Apr 17, 2020   
    P4,  N=30, Active, not recruiting, 
    Active, not recruiting --> Suspended Recruiting --> Active, not recruiting | N=90 --> 30
  • ||||||||||  carbidopa/levodopa / Generic mfg.
    Trial completion date, Trial primary completion date:  Carbidopa-levodopa in Neovascular AMD (clinicaltrials.gov) -  Mar 18, 2020   
    P2,  N=52, Recruiting, 
    Additionally, food supplements such as curcumin and niacin were effective in Parkinson's disease eradication. Trial completion date: Feb 2020 --> Feb 2021 | Trial primary completion date: Dec 2019 --> Dec 2020
  • ||||||||||  carbidopa/levodopa / Generic mfg.
    Trial completion date, Trial primary completion date:  L-DOPA vs. Placebo for Depression and Psychomotor Slowing in Older Adults (clinicaltrials.gov) -  Mar 9, 2020   
    P4,  N=90, Recruiting, 
    Trial completion date: Feb 2020 --> Feb 2021 | Trial primary completion date: Dec 2019 --> Dec 2020 Trial completion date: Nov 2021 --> Nov 2022 | Trial primary completion date: May 2021 --> Nov 2021
  • ||||||||||  carbidopa/levodopa / Generic mfg.
    Trial completion date, Trial initiation date, Trial primary completion date:  STIMO-PHARMA: Acute Effects of Pharmacological Neuromodulation on Leg Motor Activity in Patients With SCI Treated With EES (clinicaltrials.gov) -  Mar 3, 2020   
    P1,  N=8, Not yet recruiting, 
    Trial completion date: Nov 2021 --> Nov 2022 | Trial primary completion date: May 2021 --> Nov 2021 Trial completion date: Sep 2022 --> May 2023 | Initiation date: Oct 2019 --> May 2020 | Trial primary completion date: Sep 2021 --> May 2023
  • ||||||||||  Journal:  Istradefylline (Nourianz) for Parkinson's disease. (Pubmed Central) -  Feb 15, 2020   
    Trial completion date: Sep 2022 --> May 2023 | Initiation date: Oct 2019 --> May 2020 | Trial primary completion date: Sep 2021 --> May 2023 No abstract available
  • ||||||||||  carbidopa/levodopa / Generic mfg.
    Preclinical, Journal:  Novel Detection and Restorative Levodopa Treatment for Pre-Clinical Diabetic Retinopathy. (Pubmed Central) -  Feb 15, 2020   
    After two weeks of Sinemet treatment, OP implicit times were restored to control values, and these improvements persisted even after a two-week washout. We conclude that detection of dim flash OP delays could provide early detection of DR, and that Sinemet treatment may reverse retinal dysfunction.
  • ||||||||||  carbidopa/levodopa / Generic mfg., rasagiline / Generic mfg.
    Physiatric Management of a Severe Form of Autonomic Dysfunction in Parkinson's Disease: Creating the Parkinson's Toolbox () -  Feb 11, 2020 - Abstract #ISPRM2020ISPRM_1337;    
    Further implementation of pharmaceuticals continues to be explored including droxidopa.Discussions : Functional gains were limited by his symptomatic nOH...PD with debilitating nOH presents with therapeutic limitations, significant impact on quality of life, and increased mortality. Optimal care involves a true multidisciplinary approach to assess the multitude of factors involved.
  • ||||||||||  carbidopa/levodopa / Generic mfg.
    Delayed Post-Hypoxic Leukoencephalopathy: A Case Report () -  Feb 11, 2020 - Abstract #ISPRM2020ISPRM_720;    
    Case reports detail a similar clinical picture with akinetic mutism, cognitive impairments, and Parkinsonian symptoms that improved with Sinemet...At his 18-month visit he was ambulating without assistive devices and could communicate complex thoughts. He continues to make monumental improvements from baseline.
  • ||||||||||  Biomarker, Trial completion:  Measuring Parkinson's Disease Progression (clinicaltrials.gov) -  Jan 14, 2020   
    P1,  N=31, Completed, 
    He continues to make monumental improvements from baseline. Recruiting --> Completed
  • ||||||||||  Trial completion date, Trial primary completion date:  Gait Analysis in Neurological Disease (clinicaltrials.gov) -  Jan 2, 2020   
    P=N/A,  N=120, Recruiting, 
    N=300 --> 0 | Enrolling by invitation --> Withdrawn Trial completion date: Oct 2019 --> Oct 2020 | Trial primary completion date: Oct 2019 --> Oct 2020
  • ||||||||||  citalopram / Generic mfg., carbidopa/levodopa / Generic mfg.
    Trial completion, Enrollment change, Trial completion date:  SELEIS: Effect of Serotonin and Levodopa in Ischemic Stroke (clinicaltrials.gov) -  Nov 26, 2019   
    P4,  N=39, Completed, 
    Trial completion date: Oct 2019 --> Oct 2020 | Trial primary completion date: Oct 2019 --> Oct 2020 Recruiting --> Completed | N=240 --> 39 | Trial completion date: Dec 2018 --> Oct 2019
  • ||||||||||  carbidopa/levodopa / Generic mfg., naproxen ER / Generic mfg., naproxen / Generic mfg.
    Enrollment change:  Effect of L-dopa In Subacute Back Pain Population (clinicaltrials.gov) -  Sep 25, 2019   
    P4,  N=72, Completed, 
    We report the first evidence of potential anti-parkinsonian efficacy of the oral selective D1/D5 partial agonist PF-06412562 without the significant acute changes in cardiovascular parameters reported with previous D1 agonists. N=125 --> 72
  • ||||||||||  carbidopa/levodopa / generics
    Restless Genital Syndrome in a patient with Dementia with Lewy Body (Agora 2 West, Level 2) -  Sep 24, 2019 - Abstract #MDSCongress2019MDS_340;    
    It is important to keep RGS in mind –however rare- in any case with unexplained genital discomfort sensations. A dopamine agonist agent would be of benefit in relieving these symptoms.
  • ||||||||||  carbidopa/levodopa / Generic mfg.
    Enrollment closed, Enrollment change, Trial completion date, Trial primary completion date:  Carbidopa-Levodopa in Dry AMD With Geographic Atrophy (clinicaltrials.gov) -  Sep 17, 2019   
    P2,  N=7, Active, not recruiting, 
    A dopamine agonist agent would be of benefit in relieving these symptoms. Recruiting --> Active, not recruiting | N=254 --> 7 | Trial completion date: Mar 2020 --> Mar 2021 | Trial primary completion date: Dec 2019 --> Dec 2020